NFE2L2 and chronic obstructive pulmonary disease: A synthetic triterpenoid Nrf2 activator bardoxolone methyl is effective in a cigarette smoke-exposed mouse model of COPD (Sussan et al, 2009), but a phase 3 clinical trial in renal disease was terminated due to adverse effects and increased mortality (Rossing, 2013).